ArticleFundamental research2026
Tumoral IL-10-activated SHP2 in macrophages promotes mammary carcinoma progression.
Article in Fundamental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cytokine-driven modulation of WT1 and IL-10 in lung cancer progression.Translational lung cancer research · 2025Article
- Identification of conserved and tissue-restricted transcriptional profiles for lipid associated macrophages.Communications biology · 2025Article
- Identification of conserved and tissue-restricted transcriptional profiles for lipid associated macrophages (LAMs).bioRxiv : the preprint server for biology · 2024Article
- Preclinical evaluation of radiolabeled tissue factor-targeted peptide for theranostics of hepatocellular carcinoma post percutaneous ethanol injection.Theranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Src homology 2 domain-containing tyrosine phosphatase 2 (SHP2) is a non-receptor tyrosine phosphatase and acts as a convergent node for oncogenic cell-signaling cascades. SHP2 has been recognized as a breakthrough anti-tumor therapeutic target. However, it is still elusive for the role of SHP2 in manipulating tumor microenvironment for malignancy. Here, we found that SHP2 activation in tumor-associated macrophages (TAMs) paralleled mammary carcinoma progression. Co-culture system and human breast cancer specimens also showed high levels of phosphorylated SHP2 in macrophages. Conditional SHP2 knockout or pharmacological SHP2 inhibition blocked mammary carcinoma growth and reduced metastasis. More importantly, tumor-derived IL-10 induced SHP2 phosphorylation in macrophages upon the tumor-macrophage interaction. SHP2 activation rendered macrophages an immunosuppressive phenotype and attenuated their responsiveness to type I interferon. IL-10 deficiency in mammary carcinoma cells caused tumor regression, which was accompanied by the reduction of SHP2 activation in TAMs. These findings suggest a protumorigenic role of SHP2 in the crosstalk between macrophages and mammary carcinoma cells in tumor microenvironments and reveal that targeting SHP2 in macrophages could be a therapeutic approach to improve anticancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.